Publisher Correction: Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS)
暂无分享,去创建一个
[1] V. Ho,et al. Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome , 2020 .
[2] P. Richardson,et al. Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: Final Results From the International Compassionate-Use Program. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[3] P. Richardson,et al. Defibrotide for Treatment of Severe Veno-Occlusive Disease in Pediatrics and Adults: An Exploratory Analysis Using Data from the Center for International Blood and Marrow Transplant Research. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[4] E. Das-Gupta,et al. Incidence and management of hepatic severe veno-occlusive disease in 273 patients in a single centre with defibrotide , 2016, Bone Marrow Transplantation.
[5] R. D'Agostino,et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. , 2016, Blood.
[6] T. Miyamoto,et al. Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: Incidence, risk factors and outcomes , 2016, Bone Marrow Transplantation.
[7] L. Martínez,et al. CP-062 Defibrotide for the treatment of severe hepatic veno-occlusive disease. A single centre experience , 2016 .
[8] F. Locatelli,et al. Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Following Hematopoietic Stem Cell Transplantation or Chemotherapy--Results from the Italian Therapeutic Use Protocol , 2015 .
[9] G. Kang,et al. Escalation to High-Dose Defibrotide in Patients with Hepatic Veno-Occlusive Disease. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[10] J. Ruiz Ramos,et al. CP-129 Defibrotide for sinusoidal obstruction syndrome: a single centre experience , 2014 .
[11] Allen R. Chen,et al. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[12] L. Dupuis,et al. Defibrotide for the treatment of hepatic veno‐occlusive disease in children , 2007, Pediatric blood & cancer.
[13] Z. Akı,et al. Treatment of sinusoidal obstruction syndrome with defibrotide: a single-center experience. , 2007, Transplantation proceedings.
[14] A. Schulz,et al. Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention , 2004, Bone Marrow Transplantation.
[15] Allen R. Chen,et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. , 2002, Blood.
[16] T. Barbui,et al. Defibrotide for the treatment of hepatic veno‐occlusive disease: results of the European compassionate‐use study , 2000, British journal of haematology.
[17] D. Neuberg,et al. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. , 1998, Blood.